LexaGene Receives 2021 BioTech Breakthrough Award
November 02 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company
that has commercialized an instrument for automated multiplex PCR
testing for veterinary diagnostics, today announced it was named
the 2021 BioTech Breakthrough Molecular Diagnostics Solution of the
Year.
The BioTech Breakthrough Award selection committee performs a
comprehensive evaluation of life sciences and biotechnogly tools,
services, and companies identifying innovative and standout
technology that will improve the world. Award winners rise above
their competitors and are considered stand out technology in a
crowded market across many sectors. The program is open to all
individuals or companies involved in producing publicly available
products and services. Featured winners cross multiple categories,
including but are not limited to biopharma, therapeutics, genomics,
immunology, bioagriculture, and bioindustrial. Judges represented a
mix of technology, business, academic, and marketing expertise
within the industry.
Dr. Jack Regan, CEO and Founder of LexaGene stated, “We continue
to make great strides in building our brand as we break through a
crowded biotechnology market with our MiQLab™ System. This award is
specifically focused on the concept of innovation, performance,
functionality, value, and impact. I’m very proud of the strides
we’ve made as we build a product that is like no other in the
market. Our one-of-kind technology quickly and accurately diagnoses
infections and detects drug resistance allowing for effective early
treatment.”
He continued, “In just five short years, we’ve gone from a
concept on paper to a commercialized product. Recognition like the
one received from BioTech Breakthrough and the recently announced
opportunity to be a Best in Show Spotlight company at the upcoming
47th Petcare Innovation Summit, reinforces to me, our Board, and
our employees, that we have a cutting edge technology that will
impact multiple markets.”
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Investors:
Sharon Choe
Vice President
LaVoieHealthScience
schoe@lavoiehealthscience.com
(857) 241-7393
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024